ClinicalTrials.gg
CompletedNCT01924299Updated Jun 6, 2017Results posted

A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

A Phase 1 interventional study of Baricitinib and Ketoconazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to look at the effect of ketoconazole and fluconazole on how much baricitinib gets into the blood stream. The study will also look at the tolerability of baricitinib and ketoconazole when given together and the tolerability of baricitinib and fluconazole when given together.

Participants will be recruited into 1 of 2 treatment groups (Group A or Group B). Each treatment group will participate in 2 study periods. Participants will take baricitinib alone in 1 period and baricitinib with either ketoconazole or fluconazole in the other period. This study will last approximately 7 weeks.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical history and physical examination
  • Female participants not of due to surgical sterilization (at least 3 months after surgical hysterectomy, bilateral oophorectomy with or without hysterectomy, or bilateral tubal occlusion/ligation) confirmed by medical history or menopause
  • Have a of 18 to 29 kilograms per square meter (kg/m\^2), inclusive, at screening

Exclusion criteria

Exclusion Criteria:

  • Participants who have previously completed or withdrawn from this study or any other study investigating baricitinib, and have previously received the study drug
  • Have known allergies to baricitinib, ketoconazole, fluconazole, related compounds, or any components of the baricitinib, ketoconazole, or fluconazole formulations, or history of significant atopy
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have a current or recent history [less than 30 days prior to screening and/or less than 45 days prior to day of admission to Clinical Research Unit (CRU)] of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • Have (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total , or gamma glutamyl transferase (GGT) values above the upper limit of the reference range for the local laboratory at screening or day of admission to CRU
  • Have an (ANC) less than 2 times 10\^9 per liter (L) [2000 cells per microliter (μL)] at screening or day of admission to CRU. For abnormal values, a single repeat will be allowed
  • Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study (with the exception of occasional paracetamol, which will be permitted at the discretion of the investigator), or intended use of vitamin supplements from Day 1 until discharge from the CRU
  • Have used or intend to use any drugs or substances that are known to be substrates, inhibitors, or inducers of cytochrome P450 (CYP) 3A4, CYP2C9, or CYP2C19 within 30 days prior to dosing and throughout the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Baricitinib + Ketoconazole

    Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2. Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2.

    Drug: Baricitinib · Drug: Ketoconazole

  • Experimental
    Baricitinib + Fluconazole

    Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2. Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2.

    Drug: Baricitinib · Drug: Fluconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole

    Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

  2. PK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole

    Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

  3. PK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole

    Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

  4. PK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole

    Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

  5. PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole

    Time frame: Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

  6. PK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole

    Time frame: Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose

07

Results

Posted Apr 21, 2017

Participant flow

Period 1
Participant flow — Period 1
MilestoneBaricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)
Started1818
Received baricitinib1818
Completed1818
Not completed00
Period 2
Participant flow — Period 2
MilestoneBaricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)
Started1818
Received at least 1 dose of study drug1818
Received baricitinib1717
Completed1717
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame:
Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
nanograms*hour/milliliter (ng*h/mL)Baricitinib (Group A)Baricitinib + Ketoconazole (Group A)
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole720 ± 23868 ± 24
PrimaryPK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame:
Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Geometric mean · ng*h/mL
PK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
ng*h/mLBaricitinib (Group B)Baricitinib + Fluconazole (Group B)
PK: AUC(0-∞) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole698 ± 24851 ± 24
PrimaryPK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame:
Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
nanograms/milliliter (ng/mL)Baricitinib (Group A)Baricitinib + Ketoconazole (Group A)
PK: Maximum Concentration (Cmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole106 ± 27115 ± 32
PrimaryPK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame:
Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
ng/mLBaricitinib (Group B)Baricitinib + Fluconazole (Group B)
PK: Cmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole103 ± 36107 ± 38
PrimaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
Time frame:
Days 1 and 6: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole
hoursBaricitinib (Group A)Baricitinib + Ketoconazole (Group A)
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Ketoconazole1.00 (0.50 to 2.00)1.00 (0.50 to 2.00)
PrimaryPK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
Time frame:
Days 1 and 7: predose of baricitinib and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours postdose
Reported as:
Median · hours
PK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole
hoursBaricitinib (Group B)Baricitinib + Fluconazole (Group B)
PK: Tmax of Baricitinib Following Single Doses of Baricitinib Alone or Coadministered With Fluconazole1.00 (0.50 to 4.00)1.00 (0.50 to 3.00)

Adverse events

Collected over Baseline through study completion (up to Day 23).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib (Group A)—0/18 (0%)4/18 (22.2%)
Ketoconazole (Group A)—0/18 (0%)7/18 (38.9%)
Baricitinib + Ketoconazole (Group A)—0/17 (0%)4/17 (23.5%)
Baricitinib (Group B)—0/18 (0%)3/18 (16.7%)
Fluconazole (Group B)—0/18 (0%)4/18 (22.2%)
Baricitinib + Fluconazole (Group B)—0/17 (0%)6/17 (35.3%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventBaricitinib (Group A)Ketoconazole (Group A)Baricitinib + Ketoconazole (Group A)Baricitinib (Group B)Fluconazole (Group B)Baricitinib + Fluconazole (Group B)
HeadacheNervous system disorders3/186/182/171/180/181/17
NauseaGastrointestinal disorders0/180/180/170/182/180/17
Catheter site related reactionGeneral disorders0/180/181/170/180/181/17
Influenza like illnessGeneral disorders0/180/180/170/180/181/17
ArthralgiaMusculoskeletal and connective tissue disorders0/180/180/170/180/181/17
Musculoskeletal painMusculoskeletal and connective tissue disorders0/180/180/170/181/181/17
Neck painMusculoskeletal and connective tissue disorders0/180/181/170/180/180/17
CoughRespiratory, thoracic and mediastinal disorders0/180/180/170/180/181/17
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/180/180/170/180/181/17
ErythemaSkin and subcutaneous tissue disorders0/180/181/170/180/180/17

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Baricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)Total
Mean42.3 ± 15.042.7 ± 13.742.5 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)Total
Female268
Male161228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)Total
Hispanic or Latino000
Not Hispanic or Latino181836
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White161632
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Baricitinib + Ketoconazole (Group A)Baricitinib + Fluconazole (Group B)Total
United Kingdom181836
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2013
First posted
Aug 16, 2013
Start
Aug 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01924299
Responsible party
Sponsor
First posted
Aug 16, 2013
Start date
Aug 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion